Related by context. All words. (Click for frequent words.) 67 AIM HIGH 65 AVADO 63 Sorafenib HCC Assessment 63 Phase IIIb clinical 63 phase IIb clinical 63 RE LY 62 unblinding 62 subanalysis 62 phase IIb study 61 ONTARGET 61 viral kinetic 60 phase IIb trial 60 SUCCEED trial 60 Board DSMB 60 substudy 60 oral ridaforolimus 60 unblinded 60 ILLUMINATE 60 prospective randomized controlled 60 randomized Phase III 60 BCIRG 60 CARE HF 60 randomized multicenter Phase III 59 multicenter clinical 59 confirmatory clinical 59 phase IIa 59 HPTN 59 placebo controlled trials 59 confirmatory Phase III 59 multicentre randomized 59 phase IIb 59 randomized controlled clinical 59 Phase 2a trial 59 VADT 59 PRIMO CABG 59 randomized controlled clinical trials 59 placebo controlled clinical 58 BRIM3 58 multicenter Phase 58 EVEREST II 58 RE LY ® 58 registrational 58 Carotid Revascularization Endarterectomy vs. 58 HORIZONS AMI trial 58 AVERROES 58 ARBITER 6 58 pharmacodynamic effects 58 DSMB 58 unblind 58 Prostate AdenoCarcinoma Treatment 58 EmbraceAC 58 APPRAISE 58 phase IIa clinical 58 ENHANCE study 58 midstage studies 58 randomized clinical trials 58 SCD HeFT 58 Prostate Lung Colorectal 58 placebo controlled Phase III 58 NSABP C 58 multicenter randomized clinical 58 phase IIIb 57 Phase 2b study 57 clinical trial 57 PRE SURGE 57 clinical pharmacology studies 57 CUSTOM III 57 MEND CABG 57 multicenter prospective 57 PEARL SC 57 MADIT II 57 Phase #b/#a 57 CHAMPION PLATFORM 57 ASCEND HF 57 dose escalation clinical 57 Phase IIB 57 randomized multicenter 57 oral deforolimus 57 Phase Ib study 57 EMPHASIS HF trial 57 randomized trials 57 NSABP 57 ToGA 57 phase Ib 57 STRIDE PD 57 SIMPADICO 57 MADIT CRT trial 57 Phase Ib clinical 57 DAPT 57 EchoCRT 57 ELCAP 57 metastatic HRPC 57 ENDEAVOR IV 57 HCV SPRINT 57 ENDEAVOR III 57 ENRICH trial 56 randomized clinical 56 dose escalation Phase 56 placebo controlled studies 56 Sibutramine Cardiovascular Outcomes 56 randomized controlled 56 PERSEUS 56 Dose escalation 56 GAMMAGARD 56 randomized multicenter trial 56 anacetrapib 56 noninferiority 56 randomized Phase IIb 56 double blinded randomized 56 PLCO 56 dose escalation trial 56 placebo controlled Phase 56 iPrEx 56 Phase 1b trial 56 ARCOXIA 56 dose cohort 56 iniparib 56 Phase III VISTA 56 placebo controlled randomized 56 multicenter Phase II 56 APEX AMI trial 56 subgroup analyzes 56 PFO migraine 56 glatiramer acetate 56 neratinib 56 active comparator 56 multicenter placebo controlled 56 ACTIVE W 56 axitinib 56 pivotal bioequivalence 56 ASSERT trial 56 TAXUS IV 56 eptifibatide 56 NO# [002] 56 Phase IIb clinical 56 PRIMO CABG2 56 thorough QT 56 ABSORB trial 56 IMPACT DCM 56 teriflunomide 56 EDEMA4 56 Phase IIb trial 56 tolevamer 56 Phase III randomized controlled 56 riociguat 56 SABCS 56 MADIT CRT 55 PRECISE 55 NATRECOR R 55 multicenter trials 55 Phase III randomized 55 MERLIN TIMI 55 Phase 2b kidney transplant 55 Committee IDMC 55 GENASIS trial 55 selenium supplementation 55 dose escalation 55 CALGB # [001] 55 muraglitazar 55 landmark ATHENA 55 Phase 1b dose escalation 55 LymphoStat B 55 HYVET 55 dose titration 55 ENHANCE 55 SPIRIT IV 55 phase III ACCLAIM 55 PARTNER Trial 55 phase III SIMPADICO 55 PRoFESS 55 PROPEL trial 55 Phase IIb III 55 dose escalation phase 55 SYMMETRY trial 55 cediranib 55 brivaracetam 55 Phase 2b trial 55 ASTEROID 55 elotuzumab 55 HF ACTION 55 Phase IIa trial 55 LUX Lung 55 HCV RESPOND 2 55 darapladib 55 figitumumab 55 Betaferon ® 55 XL# SAR# 55 ORAL Sync 55 MGd 55 tanespimycin 55 multicenter 55 pertuzumab 55 ExTRACT TIMI 55 DSMB recommended 55 Phase IIIb 55 placebo controlled clinical trials 55 LibiGel Phase III 55 SPIRIT FIRST 55 afatinib 55 NATRECOR ® 55 multicenter randomized placebo controlled 55 NP2 Enkephalin 55 neurologic progression 55 ROCKET AF 55 multicenter randomized controlled 55 ATTRACT 55 EORTC 54 ANCHOR trial 54 multicenter study 54 multicentre 54 Phase 1b 54 TACI Ig 54 letrozole 54 ADVANCE PD 54 PLCO trial 54 trials RCTs 54 placebo controlled 54 irbesartan 54 APPROVe 54 tecarfarin 54 Phase III pivotal 54 blinded randomized controlled 54 TRA 2P 54 prospective multicenter 54 HOPE TOO 54 PROSTVAC TM 54 opioid induced bowel dysfunction 54 OBPM 54 MADIT 54 CAMMS# 54 oral FTY# 54 CLARITY study 54 cilostazol 54 temsirolimus 54 label multicenter 54 TMC# C# 54 phase Ib clinical 54 telcagepant 54 BRIM2 54 nonrandomized 54 GOUT 54 BARI 2D 54 Phase 2b clinical 54 GRAVITAS trial 54 Health Initiative WHI 54 BAY #-# 54 ponatinib 54 PreCISe 54 prospective observational 54 WHIMS 54 ACUITY trial 54 prospective multicenter randomized 54 SYNTAX trial 54 CAPRISA 54 rosuvastatin 54 SPARCL 54 Phase Ib 54 double blinded placebo 54 AIR CF2 54 Alzhemed 54 ezetimibe simvastatin 54 nab paclitaxel 54 fluvastatin 54 randomized blinded 54 DASISION 54 ENESTnd 54 ALLHAT 54 MIST II 54 assessing T DM1 54 optimal dosing 54 ticagrelor 54 enzastaurin 53 pharmacokinetics PK 53 SPIRIT III 53 Randomized controlled 53 Phase 2b clinical trials 53 Phase III trials 53 PRECISE Trial 53 Phase 2a clinical 53 MAGE A3 ASCI 53 Stenting Trial CREST 53 FDA Investigational Device 53 ascending dose 53 abatacept 53 angiographic outcomes 53 PIX# [002] 53 randomized controlled Phase 53 iclaprim 53 ACCOMPLISH 53 levosimendan 53 ECASS 53 Phase Ib II 53 GSK# [002] 53 sunitinib 53 GVAX 53 tesmilifene 53 Viramidine 53 Phase Ib clinical trials 53 Prostate Cancer Prevention 53 Phase III placebo controlled 53 Screening Trial 53 olaparib 53 zalutumumab 53 National Surgical Adjuvant 53 CURRENT OASIS 7 53 BETAS 53 pazopanib 53 Phase IIb clinical trials 53 motavizumab 53 treatment naive genotype 53 CALGB 53 ADAGIO study 53 BR.# 53 UKPDS 53 registrational trial 53 ALN VSP Phase 53 metastatic castration resistant 53 motesanib 53 PTK ZK 53 phase 2a 53 Phase IIa trials 53 NEUVENGE 53 CoFactor 53 Asentar 53 prospective randomized placebo 53 ELACYT 53 Rasilez Tekturna 53 midstage trials 53 TOLAMBA 53 multicenter phase 53 Anacetrapib 53 REALITY Trial 53 ZD# [001] 53 CHAMPION PCI 53 ACCORD Lipid 53 multicenter randomized 53 rivaroxaban 53 NCCTG N# 53 pharmacodynamics PD 53 crizotinib PF # 53 EURIDIS 53 TELCYTA 53 homocysteine lowering 53 Clinical Antipsychotic Trials 53 prospective multicentre 52 randomized controlled trials 52 Phase Ia 52 prospectively defined 52 Telcyta 52 budesonide foam 52 galiximab 52 TG MV 52 INCB# [001] 52 Phase III clinical 52 ongoing Phase 1b 52 ZOLINZA 52 cangrelor 52 EMPHASIS HF 52 prospective randomized 52 mg/m2 cohort 52 aromatase inhibitor therapy 52 gadobutrol 52 Vorapaxar 52 vandetanib 52 Subgroup analyzes 52 Corlux 52 cetuximab Erbitux 52 ENDEAVOR II 52 randomized placebo controlled 52 efficacy endpoint 52 dutasteride 52 Phase IIb trials 52 exemestane 52 Phase IIa clinical 52 PSMA ADC 52 comparator arm 52 Xelox 52 Phase III 52 Phase #b/#a trial 52 Apixaban 52 prasugrel 52 atrasentan 52 Phase IIIb study 52 lintuzumab 52 lipid lowering therapy 52 midstage clinical 52 TAXUS VI 52 TAXUS ATLAS 52 fidaxomicin Phase 3 52 rosiglitazone 52 CALGB # [002] 52 Digital Mammographic Imaging 52 PCI ExTRACT TIMI 52 ReoPro 52 IMPROVE HF 52 dacetuzumab 52 EDEMA3 52 multiple ascending dose 52 Azedra 52 Trial PCPT 52 Ixempra 52 WHEL 52 Vectibix panitumumab 52 KRAS status 52 COMFORT II 52 elective PCI 52 blinded randomized 52 EOquin TM 52 sNDA submission 52 metastatic sarcomas 52 NSABP B 52 randomized Phase 52 CIMZIA TM certolizumab pegol 52 celecoxib 52 ixabepilone 52 Phase IIb 52 registrational Phase 52 Traficet EN 52 posaconazole 52 Phase #/#a 52 zotarolimus eluting stent 52 apixaban 52 Women Ischemia Syndrome 52 randomized controlled trial 52 Phase 1b clinical 52 Phase 1a 52 MyVax 52 secondary efficacy endpoint 52 prospective randomized multicenter 52 Phase 2b 52 IIa trial 52 IMPACT IMmunotherapy 52 ATACAND 52 CRMD# 52 deforolimus 52 Xinlay 52 TRANSFORMS 52 fosbretabulin 52 FAME Study 52 clinical trials 52 eprotirome 52 STICH trial 52 tremelimumab 52 TRITON TIMI 52 confirmatory Phase 3 52 velafermin 52 chemoradiotherapy 52 tolerated dose MTD 52 valsartan 52 varespladib 52 Long Lesion 52 remission CR 52 ximelagatran 52 PRESEPT 52 randomized Phase 2b 52 Intervention Trial GAIT 52 masked placebo controlled 52 trastuzumab emtansine T DM1 52 Aortic Stenosis 52 dosage regimens 52 recurrent glioblastoma multiforme 51 candesartan 51 antibody MAb 51 RE LY trial 51 carotid artery stenting 51 denufosol 51 BLA submission 51 Degarelix 51 ERSPC 51 Novartis Zometa 51 abiraterone 51 RSD# oral 51 Dasatinib 51 Ostarine 51 COSIRA trial 51 efficacy 51 EQUIP OB 51 clinical endpoints 51 recurrent glioma 51 vicriviroc 51 OvaRex ® MAb 51 bicifadine 51 Tanespimycin 51 GetGoal Phase III 51 oral rivaroxaban 51 elagolix 51 dietary questionnaires 51 Androxal TM 51 ataluren 51 APTIVUS 51 Pemetrexed 51 relapsed MCL 51 rosuvastatin #mg 51 avosentan 51 Dacogen injection 51 custirsen 51 desmoteplase 51 rALLy clinical trial 51 dose dose escalation 51 BLA filing 51 CLIRS trial 51 canakinumab 51 Alpharadin 51 lomitapide 51 Zerenex 51 phase IIb III 51 prospective observational studies 51 PREVENT IV 51 trial evaluating PRX# 51 endothelin antagonists 51 observational study 51 dose cohorts 51 YONDELIS 51 reboxetine 51 LUMINATE 51 Edge STudy 51 rNAPc2 51 Intervention Effectiveness 51 goserelin 51 Aflibercept 51 antiplatelet therapy 51 non inferiority 51 HuMax EGFr 51 randomized crossover 51 vitamin D supplementation 51 Phenoptin 51 TASKi2 51 postapproval 51 TLK# 51 PROTECT II 51 Tocosol Paclitaxel 51 MAXY alpha 51 alvimopan 51 pegylated interferon alfa 2b 51 Alfimeprase 51 placebo controlled multicenter 51 ENDEAVOR clinical 51 HAART regimens 51 Radiation Therapy Oncology 51 CRESTOR #mg 51 Clinical trials 51 canagliflozin 51 subcutaneous PRO 51 OPT CHF 51 PROactive study 51 GSK# [001] 51 RIO Lipids 51 Clinical Outcomes Utilizing Revascularization 51 CHARM Added 51 pharmacokinetic PK study 51 multicenter randomized double 51 senicapoc 51 TASKi3 51 REG1 51 sunitinib malate 51 antitumor effect 51 Folfox 51 BRAF inhibitor 51 peg interferon 51 ongoing Phase IIIb 51 forodesine 51 interferon beta 1b 51 ASPIRE HIGHER 51 bapineuzumab 51 ACRIN 51 LY# [003] 51 ORMD 51 PSN# [002] 51 morphometric vertebral fractures 51 pomalidomide 51 Desmoteplase 51 TEMSO 51 label multicenter randomized 51 AIR CF1 51 NCT# ClinicalTrials.gov 51 attain statistical significance 51 INCB# [002] 51 VITAL Trial 51 Diamyd r vaccine 51 FTY# 51 Tarceva TM 51 APTIVUS r 51 Phase #b/#a clinical 51 Mylotarg 51 ridaforolimus 51 AZOR 51 Zolinza 51 IND submission 51 modified REGENESIS Phase IIb 51 HeFT 51 #:# randomization 51 tolvaptan 51 MEND CABG II 50 oral methylnaltrexone 50 dirucotide 50 RECORD1 50 Tavocept 50 Torisel 50 satraplatin Phase 50 Canvaxin 50 adenoma recurrence 50 sulodexide 50 DU #b 50 rALLy trial 50 aflibercept 50 multicentre randomized double 50 severe hypercholesterolemia 50 androgen suppression 50 everolimus eluting stents 50 INSPIRE Trial Phase III 50 REVLIMID lenalidomide 50 dose regimens 50 IMA# 50 CLL8 50 secondary efficacy endpoints 50 Phase III multicenter 50 PANVAC VF 50 dexanabinol 50 label multicenter Phase 50 Polyp Prevention Trial 50 label dose escalation 50 eplerenone 50 Maximum Tolerated Dose MTD 50 Observational studies 50 Vytorin 50 TDF FTC 50 Ophena TM 50 Tolamba 50 ROTATEQ 50 PMA submission 50 Endeavor drug eluting 50 teriparatide 50 postoperative chemotherapy 50 TAXUS Liberte Stent 50 CLIRS 50 Genz # 50 Pirfenidone 50 Subgroup analysis 50 tocilizumab 50 Multiethnic Study 50 Phase #/#a clinical 50 adjuvant colon cancer 50 TroVax 50 PXD# 50 Elocalcitol 50 APEX PD 50 glufosfamide 50 post hoc 50 Cholesterol Levels SPARCL 50 nonclinical studies 50 Zybrestat 50 Evaluation WISE 50 Atrasentan 50 radiographic outcomes 50 liver resection 50 valopicitabine 50 trabectedin 50 telmisartan 50 randomized 50 Velcade bortezomib 50 eltrombopag 50 intensive statin therapy 50 Hepatocellular Carcinoma HCC 50 OVATURE 50 rosiglitazone Avandia 50 AEG# 50 visilizumab 50 tasocitinib 50 Relovair 50 darusentan 50 clopidogrel Plavix 50 cardioprotective effects 50 beta blocker therapy 50 MIRCERA 50 HER2 positive metastatic breast 50 CYPHER Stent 50 olmesartan 50 tipranavir 50 Val HeFT 50 solanezumab 50 meta analysis pooling 50 PRECiSE 50 metastatic hormone refractory 50 meta analyzes 50 PRADAXA 50 #mg dosing group 50 IMPACT DCM clinical 50 mapatumumab 50 Allovectin 7 ® 50 ritonavir boosted 50 Ophena 50 CRLX# 50 HGS ETR2 50 clinically meaningful 50 pharmacokinetic PK 50 COPAXONE R 50 inhibitor RG# 50 AZILECT R 50 HGS ETR1 50 Aggressive Reduction 50 postmarketing surveillance 50 Intervention Effectiveness CATIE 50 Stedivaze 50 preoperative chemotherapy 50 QTc prolongation 50 Genasense ® 50 lorcaserin Phase 50 chromium supplementation 50 lasofoxifene 50 Adenoma Prevention 50 pivotal Phase III 50 prospectively randomized 50 BEZ# 50 CATIE 50 Diamyd ® 50 GLPG# 50 TAXUS TM 50 Fablyn 50 antiangiogenic therapy 50 randomized multicentre 50 clevidipine 50 Group RTOG 50 sorafenib Nexavar 50 tapentadol ER 50 NEVO 50 apremilast 50 ALTTO 50 ritonavir boosted danoprevir 50 metreleptin 50 Zenvia Phase III 50 blinded randomized placebo controlled 50 virologic response 50 safety tolerability pharmacokinetic 50 DES implantation 50 AIR CF3 50 evaluable subjects 50 angiographic follow 50 crizotinib 50 PD LID 50 NEO3 50 dabigatran etexilate 50 FOLPI 50 HIVNET 50 ONCONASE R 50 Cohort Study MACS 50 Orexigen Contrave 50 Cochrane Systematic Review 50 Framingham Offspring Study 50 ocrelizumab 50 Rosuvastatin 50 Xarelto 50 arzoxifene 50 pharmacodynamics 50 viral kinetics 50 nesiritide 50 oxymorphone ER 50 eculizumab therapy 50 Lipid Lowering Treatment 50 Phase III registrational 50 Rivaroxaban 50 sentinel node biopsy 50 vismodegib 50 prospective observational cohort 50 ganetespib 50 investigational protease inhibitor 50 Trexima 50 NeuroFlo 50 Celecoxib APC trial 50 PFO closure 49 bronchial thermoplasty 49 alvespimycin 49 lapatinib Tykerb 49 recurrent VTE 49 ivabradine 49 ABCSG 49 prespecified 49 CATIE AD 49 intermittent dosing 49 catheter occlusion 49 REVIVE Diabetes 49 PROMACTA 49 montelukast 49 Phase 1a clinical 49 IL# PE#QQR 49 ancrod 49 PREGNANT Study 49 CR# vcMMAE 49 warfarin therapy 49 AVOREN 49 cisplatin vinorelbine 49 Hydroxyurea 49 Trandolapril 49 Actimmune ® 49 odanacatib 49 Phase 2b randomized 49 meta analysis 49 lumiracoxib 49 multicenter multinational 49 Ovarian Cancer Screening 49 MAA submission 49 blind randomized 49 NEVO RES 49 carotid endarterectomy CEA 49 ustekinumab 49 Phase #/#a trial 49 pivotal Phase 49 recurrent GBM 49 Diabetes ACCORD 49 Thorough QT 49 dexpramipexole 49 Zenvia ™ 49 IFN alfa 49 Multicenter Automatic Defibrillator Implantation 49 rindopepimut 49 cannabinor 49 SCH # 49 ABSORB clinical 49 doxorubicin docetaxel 49 Sequenced Treatment Alternatives 49 SVR# 49 Tumor Response 49 symptomatic VTE 49 Brilinta 49 bile duct tumor 49 composite endpoint 49 docetaxel chemotherapy 49 NLX P# 49 MS relapses 49 ALSYMPCA 49 RoACTEMRA 49 liprotamase 49 observational cohort 49 Phase 2a 49 Tyrima 49 desvenlafaxine succinate 49 ConclusionThis 49 Phase 1b clinical trials 49 ruxolitinib 49 AREDS 49 midstage clinical trials 49 ezetimibe 49 verteporfin 49 DMIST 49 Screening Trial DMIST 49 vaccine Stimuvax 49 Ranolazine 49 R# #mg BID 49 mcg dose 49 recurrent malignant glioma 49 CUSTOM II 49 Relieve Depression 49 Neuvenge 49 colesevelam HCl 49 Phase III TRIST 49 HCV NS5B polymerase 49 daclizumab 49 RIO Diabetes 49 controlled multicenter 49 fondaparinux 49 GALNS 49 NOX E# 49 XmAb# 49 Phase Ib IIa clinical 49 postintervention 49 BR.# study 49 LITHE 49 multicentre study 49 ezetimibe Zetia 49 calcium supplementation 49 ACTEMRA 49 Plicera 49 EDEMA3 trial 49 Cloretazine R VNP#M 49 Motesanib 49 samalizumab 49 resminostat 49 relapsing MS 49 MERIT ES 49 Targretin 49 multicenter Phase III 49 CYPHER ® Stent 49 MVax R 49 EndoTAG TM -1 49 SAR# [004] 49 REVIVE TA 49 masitinib 49 Dialysis Outcomes 49 insulin detemir 49 Sensitivity analyzes 49 multicentre randomized controlled 49 PREDICTIVE 49 GLP toxicology studies 49 undergone radical prostatectomy 49 INTERHEART study 49 blinatumomab 49 Sulonex 49 dosing cohort 49 ENHANCE trial 49 preclinical efficacy 49 KRAS mutations occur 49 ACTEMRA TM 49 rFVIIa 49 IMGN# 49 Sirolimus eluting Coronary Stent 49 HGS# 49 Amrubicin 49 ONTARGET R 49 titration phase 49 DCCT 49 pharmacodynamic profile 49 Phase IIa 49 Wisconsin Sleep Cohort 49 simvastatin ezetimibe 49 pharmacokinetic pharmacodynamic 49 Heplisav 49 renal flares 49 VIRAMUNE XR 49 rasagiline 49 PITX2 methylation 49 Xyotax 49 OncoVex 49 diabetic neuropathic pain 49 Phase III psoriasis 49 trastuzumab DM1 49 RRMS patients 49 International Verapamil SR 49 Egrifta 49 Recentin 49 dimebon 49 FROVA 49 pegylated liposomal doxorubicin 49 Protelos 49 dosing cohorts 49 coxib 49 losartan 49 ACOSOG Z# 49 Randomized Evaluation 49 otelixizumab 49 pharmacokinetic PK profile 49 ADMIRE HF 49 controlled multicenter Phase 49 peginesatide 49 de novo kidney transplant 49 relapsed MM 49 ACCORD 49 depsipeptide 49 HspE7 49 Ovarian PLCO Cancer 49 ruboxistaurin 49 VA# [002] 49 Stenting Trial 49 virologic 49 abiraterone acetate 49 alogliptin 49 ARIMIDEX 49 OncoVEX GM CSF 49 SIMPADICO trial 49 NDA submission 49 farletuzumab 49 fostamatinib 49 efficacy endpoints 49 FASLODEX 49 ipsilateral stroke 49 elesclomol 49 PegIFN RBV 49 palifosfamide 49 prospective multicenter study 49 Xgeva 49 reslizumab 49 rivaroxaban Xarelto 49 tramiprosate Alzhemed TM 49 AZILECT ® 49 clazosentan 49 prospective nonrandomized 49 mg kg dose 49 lymphadenectomy 49 RCTs 49 Secondary endpoints 49 vemurafenib 49 Pivotal Clinical Trial 49 Femara letrozole 49 Secondary efficacy endpoints 49 sitagliptin 49 candidate CRLX# 49 dronedarone 49 vidofludimus 48 liver transplant recipients 48 label dose titration 48 zoledronic acid 48 cetrorelix pamoate 48 CARDIA study 48 PREZISTA r 48 atherosclerotic renal artery stenosis 48 pharmacoeconomic analysis 48 docetaxel Taxotere ® 48 Gynecologic Oncology Group 48 methylnaltrexone 48 Dabigatran 48 VIR#